Browse > Article
http://dx.doi.org/10.5352/JLS.2016.26.12.1383

Induction of c-Jun Expression by Breast Cancer Anti-estrogen Resistance-3 (BCAR3) in Human Breast MCF-12A Cells  

Oh, Myung-Ju (Hazardous Substances Analysis Division, Seoul Regional Food and Drug Administraion, Ministry of Food and Drug Safety)
Kim, Ji-Hyun (College of Nanoscience and Nanotechnology, Pusan National University)
Jhun, Byung Hak (College of Nanoscience and Nanotechnology, Pusan National University)
Publication Information
Journal of Life Science / v.26, no.12, 2016 , pp. 1383-1391 More about this Journal
Abstract
Anti-estrogen drugs such as tamoxifen have been used for treating patients with ER-positive, early breast cancer. However, resistance to anti-estrogen treatment is inevitable in most patients. Breast cancer anti-estrogen resistance-3 (BCAR3) has been identified as the protein responsible for the induction of tamoxifen resistance in estrogen-dependent human breast cancer. We have previously reported that BCAR3 regulates the cell cycle progression and the signaling pathway of EGF and insulin leading to DNA synthesis. In this study, we investigated the functional role of BCAR3 in regulating c-Jun transcription in non-tumorigenic human breast epithelial MCF-12A cells. A transient transfection of BCAR3 increased both the mRNA and protein of c-Jun expression, and stable expression of BCAR3 increased c-Jun protein expression. The overexpression of BCAR3 directly activated the promoter of c-jun, AP-1, and SRE but not that of $NF-{\kappa}B$. Furthermore, single-cell microinjection of BCAR3 expression plasmid in the cell cycle-arrested MCF-12A cells induced c-Jun protein expression, and co-injection of dominant negative mutants of Ras, Rac, and Rho suppressed the transcriptional activity of c-Jun in the presence of BCAR3. Furthermore, stable expression of BCAR3 increased the proliferation of MCF-12A cells. The microinjection of inhibitory materials such as anti-BCAR3 antibody and siRNA BCAR3 inhibited EGF-induced c-Jun expression but did not affect IGF-1 induced upregulation of c-Jun. Taken together, we propose that BCAR3 plays a crucial role in c-Jun protein expression and cell proliferation and that small GTPases (e.g., Ras, Rac, and Rho) are required for the BCAR3-mediated activation of c-Jun expression.
Keywords
Anti-estrogen resistance; BCAR3; breast cancer; c-Jun expression; EGF;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shaulian, E. and Karin, M. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, E131-136.   DOI
2 Smith, L. M., Wise, S. C., Hendricks, D. T., Sabichi, A. L., Bos, T., Reddy, P., Brown, P. H. and Birrer, M. J. 1999. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18, 6063-6070.   DOI
3 van Agthoven, T., Godinho, M. F., Wulfkuhle, J. D., Petricoin 3rd, E. F. and Dorssers, L. C. 2012. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int. J. Cancer 131, 1998-2007.   DOI
4 van Agthoven, T., van Agthoven, T. L., Dekker, A., van der Spek, P. J., Vreede, L. and Dorssers, L. C. 1998. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J. 17, 2799-2808.   DOI
5 Vleugel, M. M., Greijer, A. E., Bos, R., van der Wall, E. and van Diest, P. J. 2006. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 37, 668-674.   DOI
6 Wallez, Y., Riedl, S. J. and Pasquale, E. B. 2014. Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance. J. Biol. Chem. 289, 10431-10444.   DOI
7 Wilson, A. L., Schrecengost, R. S., Guerrero, M. S., Thomas, K. S. and Bouton, A. H. 2013. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS ONE 8, e65678.   DOI
8 Xu, Y., Zou, S. T., Zhu, R., Li, W., Gu, C. W., Wei, S. H., Xie, J. M. and Wu, H. R. 2013. Inhibition of proliferation of estrogen receptor positive MCF7 human breast cancer cells by tamoxifen through cJun transcription factors. Mol Med. Rep. 7, 1283-1287.   DOI
9 Zhao, C., Qiao, Y., Jonsson, P., Wang, J., Xu, L., Rouhi, P., Sinha, I., Cao, Y., Williams, C. and Dahlman-Wright, K. 2014. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res. 74, 3983-3994.   DOI
10 Zhang, Y., Pu, X., Shi, M., Chen, L., Song, Y., Qian, L., Yuan, G., Zhang, H., Yu, M., Hu, M., Shen, B. and Guo, N. 2007. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 7, 145.   DOI
11 Ibrahim, Y. H. and Yee, D. 2004. Insulin-like growth factor-I and cancer risk. Growth Horm. IGF Res. 14, 261-269.   DOI
12 Alani, R., Brown, P., Binetruy, B., Dosaka, H., Rosenberg, R. K., Angel, P., Karin, M. and Birrer, M. J. 1991. The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol. Cell. Biol. 11, 6286-6295.   DOI
13 Babu, R. L., Naveen Kumar, M., Patil, R. H., Devaraju, K. S., Ramesh, G. T. and Sharma, S. C. 2013. Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation. Mol. Cell. Biochem. 380, 143-151.   DOI
14 Boyd, D. B. 2003. Insulin and cancer. Integr. Cancer Ther. 2, 315-329.   DOI
15 Cai, D., Iyer, A., Felekkis, K. N., Near, R. I., Luo, Z., Chernoff, J., Albanese, C., Pestell, R. G. and Lerner, A. 2003. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 63, 6802-6808.
16 Cross, A. M., Wilson, A. L., Guerrero, M. S., Thomas, K. S., Bachir, A. I., Kubow, K. E., Horwitz, A. R. and Bouton, A. H. 2016. Breast cancer antiestrogen resistance 3-p130Cas interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene advance online publication, 25 April 2016 (DOI:10.1038/onc.2016.123).   DOI
17 Domann, F. E., Levy, J. P., Birrer, M. J. and Bowden, G. T. 1994. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ. 5, 9-16.
18 Early Breast Cancer Trialists' Collaborative 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784.   DOI
19 Felekkis, K. N., Narsimhan, R. P., Near, R., Castro, A. F., Zheng, Y., Quilliam, L. A. and Lerner, A. 2005. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain- dependent manner. Mol. Cancer Res. 3, 32-41.
20 Gotoh, T., Cai, D., Tian, X., Feig, L. A. and Lerner, A. 2000. p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. J. Biol. Chem. 275, 30118-30123.   DOI
21 Johnson, R., Spiegelman, B., Hanahan, D. and Wisdom, R. 1996. Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell. Biol. 16, 4504-4511.   DOI
22 Lo, H. W., Hsu, S. C. and Hung, M. C. 2006. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 95, 211-218.   DOI
23 Pietras, R. J. 2003. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor- associated vasculature. Breast J. 9, 361-373.   DOI
24 Mace, P. D., Wallez, Y., Dobaczewska, M. K., Lee, J. J., Robinson, H., Pasquale, E. B. and Riedl, S. J. 2011. NSP-Cas protein structures reveal a promiscuous interaction module in cell signaling. Nat. Struct. Mol. Biol. 18, 1381-1387.   DOI
25 Meng, Q. and Xia, Y. 2011. c-Jun, at the crossroad of the signaling network. Protein Cell 2, 889-898.   DOI
26 Near, R. I., Zhang, Y., Makkinje, A., Vanden Borre, P. and Lerner, A. 2007. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. J. Cell. Physiol. 212, 655-665.   DOI
27 Oh, M. J., van Agthoven, T., Choi, J. E., Jeong, Y. J., Chung, Y. H., Kim, C. M. and Jhun, B. H. 2008. BCAR3 regulates EGF-induced DNA synthesis in normal human breast MCF-12A cells. Biochem. Biophys. Res. Commun. 375, 430-434.   DOI
28 Oh, M. J., Yi, S. J., Kim, H. S., Kim, J. H., Jeong, Y. H., van Agthoven, T. and Jhun, B. H. 2013. Functional roles of BCAR3 in the signaling pathways of insulin leading to DNA synthesis, membrane ruffling and GLUT4 translocation. Biochem. Biophys. Res. Commun. 441, 911-916.   DOI
29 Schiff, R., Reddy, P., Ahotupa, M., Coronado-Heinsohn, E., Grim, M., Hilsenbeck, S. G., Lawrence, R., Deneke, S., Herrera, R., Chamness, G. C., Fuqua, S. A., Brown, P. H. and Osborne, C. K. 2000. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. 92, 1926-1934.   DOI
30 Schrecengost, R. S., Riggins, R. B., Thomas, K. S., Guerrero, M. S. and Bouton, A. H. 2007. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res. 67, 6174-6182.   DOI